Current exosome manufacturing relies on bulk isolation methods that fail to distinguish between therapeutically potent and pathological subpopulations, creating a critical translational bottleneck [PMC12847281]. The prevailing assumption is that functional heterogeneity stems from variable cargo loading—some exosomes carry anti-inflammatory miRNAs (miR-124, BDNF) [explorationpub.com/ent/Article/1004137] while others propagate toxic proteins like α-synuclein [PMC12847281]. This cargo-centric view, however, overlooks a fundamental biophysical layer: membrane composition dictates both cellular targeting and cargo release kinetics, potentially serving as the primary determinant of therapeutic function.

Hypothesis: Therapeutic exosome subpopulations—defined by their capacity to suppress NLRP3 inflammasome [PMC12847281] or promote M2 microglial polarization via NRF2 [PMC12220696]—possess distinct lipid raft domains with higher cholesterol:sphingomyelin ratios and specific phosphatidylserine exposure patterns. These membrane properties govern two key functions: 1) preferential uptake by target neurons or microglia via receptor-dependent endocytosis, and 2) controlled intracellular release of therapeutic cargo (e.g., catalase, miR-124) from endosomes [PMC10216928]. Pathological exosomes carrying toxic aggregates likely exhibit different membrane fluidity and lipid ordering, leading to inefficient targeting or premature cargo degradation.

This hypothesis extends current knowledge by proposing that membrane biophysics—not just cargo content—determines therapeutic outcome. It directly challenges the field's cargo-centric engineering approaches [PMC10216928][dovepress.com/IJN] by suggesting that membrane modification must precede or accompany cargo loading for optimal efficacy. The mechanistic link: lipid raft integrity influences exosome stability in circulation, cellular uptake pathways, and intracellular trafficking routes, all of which modulate whether an exosome delivers its payload to the correct compartment in the correct cell type.

Testable predictions:

1. Isolation: Density gradient ultracentrifugation combined with detergent (e.g., methyl-β-cyclodextrin) fractionation will separate exosomes into subpopulations with distinct cholesterol content and membrane fluidity (measured by fluorescence anisotropy). The high-cholesterol subpopulation will show superior NLRP3 suppression in microglial assays.
2. Targeting: Therapeutic exosome subpopulations will demonstrate higher binding affinity for neurons overexpressing specific lipid raft-associated receptors (e.g., PrPᶜ or integrins), measurable via flow cytometry with receptor-blocking antibodies.
3. Efficacy: In a 6-OHDA Parkinson's model, intra-nigral injection of sorted, high-raft exosomes will show greater TH⁺ neuron protection and behavioral recovery compared to an equivalent particle count of unsorted exosomes, with the effect blocked by pre-treatment with a membrane fluidity-disrupting agent (e.g., filipin).
4. Safety: Pathological subpopulations (low-raft) will exhibit higher α-synuclein seeding activity in biosensor cell lines, confirming the functional stratification.

Falsification: If no correlation exists between membrane properties and therapeutic potency—if sorted subpopulations show equivalent NLRP3 suppression or neuronal protection—then cargo, not membrane biophysics, is the primary functional determinant. This would redirect efforts toward cargo engineering over membrane optimization.

This approach directly addresses the "functional stratification and quality control" gap [PMC12847281] by proposing a scalable, mechanism-based biomarker (membrane lipid signature) for potency-based selection, moving the field beyond particle counts toward functionally characterized, GMP-manufacturable products.